We believe that cardiovascular health should be accessible to everyone, everywhere.
Reduce the gap in arrhythmia diagnosis worldwide
In the world, 100 million tests are not carried out every year. 1, 2, 3
In Brazil: 20 million people have arrhythmias, only 2 million perform Holter tests. 12, 13, 14
Quoretech exists to eliminate the delays, inaccessibility, and inaccuracies in arrhythmia diagnosis, saving lives and improving quality of care for millions worldwide.
How can we transform the cardiovascular diagnosis journey?
Advanced and accessible technology at the point of service.
A complete platform powered by AI.
Scalable business model with no initial investment required
Greater patient satisfaction: NPS of 95.9.
Our beliefs
People first
We prioritize patients, partners, and team members in all decisions and actions.
Think big - think daring
We aim for transformative impact, challenging traditional models with innovative solutions.
Endless improvement
We embrace a mindset of continuous learning, iteration, and excellence across all operations.
Quick learning
We adapt rapidly by learning from data, feedback, successes, and failures.
Key moments
We recognize and honor milestones and achievements, reinforcing a positive and motivated culture.
Simplicity
We design products, processes, and communications to be intuitive, efficient, and user-friendly, avoiding unnecessary complexity.
References
1. Worldometer, Current World Population, Available at: [https://www.worldometers.info/world-population/], Accessed on: 25April2025
2. Karamitanha F., et al, Difference Between Various Countries in Mortality and Incidence Rate of the Atrial Fibrillation Based on Human Development Index in Worldwide: Data From Global Burden of Disease 2010-2019, Current Problems in Cardiology Volume 48, Issue 1, January 2023
3. Van Gelder I. C, et al, 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), European Heart Journal (2024) 00, 1-101, https://doi.org/10.1093/eurheartj/ehae176 and Risks, 1990-2022100000.
4.Known S., et al, Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study, J Med Internet Res. 2022 May; 24(5): e37970. Published online 2022 May 9. doi: 10.2196/37970: 10.2196/37970.
5. Kim J. Y., et al, The efficacy of detecting arrhythmia is higher with 7-day continuous electrocardiographic patch monitoring than with 24-h Holter monitoring, Journal of Arrhythmia, Received: January 3, 2023 | Revised: April 13, 2023 | Accepted: April 20, 2023, DOI: 10.1002/joa3.12865.
6. Cadastro Nacional de Estabelecimentos de Saúde (CNES), Consulta Estabelecimentos, Name with "COR" or "CARDIO", median of establishments, Available at: [https://cnes.datasus.gov.br/], accessed on 02May2025.
7. Hospital Israelita Albert Einstein, A Comparative study of an innovative 3-lead wireless water resistant Holter system and a conventional Holter system, Available at: [https://clinicaltrials.gov/study/NCT04723355?term=Quoretech&rank=1]; Access on: 25April2025
8. Data on File, Quoretech July/21
9. Yenikomshian M., et al, Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review, Curr Med Res Opin. 2019 Oct;35(10):1659-1670. doi: 10.1080/03007995.2019.1610370. Epub 2019 May 28.
10. Leclercq C., et al, Wearables, telemedicine, and artificial intelligence in arrhythmias and heart failure: Proceedings of the European Society of Cardiology Cardiovascular Round Table, EP Europace, Volume 24, Issue 9, September 2022, Pages 1372-1383, https://doi.org/10.1093/europace/euac05
11. ROL_ANS, Available at:: [https://www.ans.gov.br/ROL-web/], Accessed on: 25April2025
12. SOBRAC, The life of a cardiac arrhythmia patient, Available at: [https://sobrac.org/publico-geral/sdrfvesfvs/], Access on: 25April2025
13. ANS, TISS Data Panel, Procedures 2024, Available at:: [https://app.powerbi.com/view?r=eyJrIjoiZGVjMDI2NjItNTUzMS00OWJkLTgwNjMtOTJmNTVlYzYwMTg0IiwidCI6IjlkYmE0ODBjLTRmYTctNDJmNC1iYmEzLTBmYjEzNzVmYmU1ZiJ9], Access on: 25April2025
14. DATASUS, AMBULATORY PRODUCTION OF THE SUS - BRAZIL - BY PLACE OF CARE, HOLTER, Available at: [http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sia/cnv/qabr.def], Access on: 25April2025
